Compare · AXSM vs CAPR
AXSM vs CAPR
Side-by-side comparison of Axsome Therapeutics Inc. (AXSM) and Capricor Therapeutics Inc. (CAPR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXSM and CAPR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AXSM is the larger of the two at $10.76B, about 22.3x CAPR ($482.0M).
- Over the past year, AXSM is up 69.6% and CAPR is up 28.4% - AXSM leads by 41.2 points.
- CAPR has been more active in the news (10 items in the past 4 weeks vs 6 for AXSM).
- AXSM has more recent analyst coverage (25 ratings vs 20 for CAPR).
- Company
- Axsome Therapeutics Inc.
- Capricor Therapeutics Inc.
- Price
- $205.46-0.02%
- $8.30+22.13%
- Market cap
- $10.76B
- $482.0M
- 1M return
- -13.84%
- +18.73%
- 1Y return
- +69.59%
- +28.36%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 6
- 10
- Recent ratings
- 25
- 20
Axsome Therapeutics Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Capricor Therapeutics Inc.
Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in preclinical stage for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the development of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.
Latest AXSM
- SEC Form 10-Q filed by Axsome Therapeutics Inc.
- Axsome Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
- Chief Executive Officer Tabuteau Herriot exercised 49,664 shares at a strike of $4.95 and sold $10,538,305 worth of shares (49,664 units at $212.19) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Axsome Therapeutics Inc.
- SEC Form 144 filed by Axsome Therapeutics Inc.
- BMO Capital Markets initiated coverage on Axsome Therapeutics with a new price target
- Axsome Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
- Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
Latest CAPR
- Capricor Therapeutics upgraded by Oppenheimer with a new price target
- Capricor Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA
- SEC Form 10-Q filed by Capricor Therapeutics Inc.
- These Biotech Breakouts and Squeeze Setups Could Be Just Getting Started
- Capricor Therapeutics upgraded by Cantor Fitzgerald with a new price target
- Capricor Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13
- SEC Form SCHEDULE 13G filed by Capricor Therapeutics Inc.